HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
INSIDE INDUSTRY
GSK opens new state-of-the-art pharmaceutical manufacturing facility in Singapore
Opening of the continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

As part of GSK and Singapore’s Economic Development Board (GSK-EDB) 10-year Singapore Manufacturing Roadmap, GSK opened new state-of-the-art manufacturing facilities in Singapore following a S$130 million investment.

The launch was officiated by Trade and Industry Minister Chan Chun Sing and Mr Regis Simard, President of Pharma Supply Chain. The new facilities are in GSK’s Jurong site and include two continuous manufacturing facilities, and an expansion of one of the site’s production buildings. The development will enable the site, to accelerate the supply of new breakthrough medicines to patients globally.

As part of GSK Jurong’s R&D Pilot Plan, the new continuous manufacturing facilities will strengthen the site’s capability for drug manufacture by allowing faster production of Active Pharmaceutical Ingredients (APIs) for clinical trials. The first New Chemical Entity (NCE) to be developed at the new facility will be Daprodustat, a new oral treatment for anaemia associated with chronic kidney disease. The new manufacturing process is expected to reduce production time of Daprodustat, enabling faster turnaround time.

The expansion of the production building which makes APIs for HIV medicines will enhance GSK’s capability to produce Dolutegravir, a key GSK asset for HIV treatment. The new facilities also engages the development of digital technologies in the manufacturing process to drive productivity improvement.

The investment demonstrates GSK’s commitment to Singapore as a key manufacturing and supply site for GSK’s global pharmaceutical business and a testbed for advanced manufacturing technology.

Click here for the complete issue.

NEWS CRUNCH  
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
news The rise of personalised nutrition
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy